Clinical trial · Observational
Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors
Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors: Propensity Score Matching
NCT06621147CI-TRIAL-00081167MLA-MNSCLCNETcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer - Non Small Cell | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).
- description
- Overall survival refers to the duration of time from the start of diagnosis until death from any cause. It is a common endpoint used in clinical trials and medical research, particularly in oncology, to measure the effectiveness of a treatment or intervention. Overall survival provides a comprehensive picture of how well patients are doing and is often expressed as a percentage or a median time (e.g., the median overall survival time).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologic Diagnosis of Non-Small Cell Neuroendocrine Carcinoma * Known Surgical Information Exclusion Criteria: * Small cell lung cancer * Age less than 18 years
References
Publications (0)
Data not yet available
No reference posted for this study.